Hyundai Pharmaceutical Co (XKRX:004310) Debt-to-EBITDA : 5.24 (As of Feb. 2024)

Hyundai Pharmaceutical Co Debt-to-EBITDA Chart

Hyundai Pharmaceutical Co Annual Data
	Trend	Nov14	Nov15	Nov16	Nov17	Nov18	Nov19	Nov20	Nov21	Nov22	Nov23
Debt-to-EBITDA		Get a 7-Day Free Trial					3.68	3.32	44.48	3.89	2.96

Hyundai Pharmaceutical Co Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-EBITDA	Get a 7-Day Free Trial															2.80	2.23	3.22	9.78	5.24

Competitive Comparison of Hyundai Pharmaceutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Hyundai Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyundai Pharmaceutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hyundai Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hyundai Pharmaceutical Co's Debt-to-EBITDA falls into.

Hyundai Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hyundai Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Nov. 2023 is calculated as

Hyundai Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.

Hyundai Pharmaceutical Co  (XKRX:004310) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Hyundai Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hyundai Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyundai Pharmaceutical Co (XKRX:004310) Business Description